AzurRx BioPharma, Inc.
Biotech — is developing non-systemic oral biologics to treat patients with gastrointestinal disorders. Focused on developing its lead drug product candidate, MS1819, a recombinant lipase enzyme that treats exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. AzurRx is headquartered in New York, NY, with scientific operations in Langlade, France, and clinical operations in Hayward, California.
AzurRx is listed on the NASDAQ under the symbol AZRX.
Three reasons to invest in AzurRx Pharma
- The company has a strong patent family — with more than one patent, the company has a pipeline of intellectual property to fuel its growth.
- The market is sizeable, worth well over US$2 billion — the company believes it could capture 40 to 50 per cent of this market share.
- The stock is significantly undervalued — most of AzurRx’s peers are trading at three to four times their sales revenue.
2 Minute Company Overview
For more information about AzurRx BioPharma, please contact Martin Krusin, SVP of Corporate Development at (646) 713-2924
